Statin Intolerance

Episode 5: Statin Intolerance in Focus: Navigating Side Effects, Patient Concerns, and the Path to Optimal LDL Lowering

When two past NLA Presidents and seasoned podcast hosts sit down together, the conversation is bound to be something special.…

Statin Intolerance: A Vexing and Elusive Clinical Problem

Statin Intolerance, Statin Defiance, Nocebo Effect…Does it Really Matter?

The Lipid Panel – Statins and Intracerebral Hemorrhage

Managing the Statin-Intolerant Patient: Low-Dose/Low-Frequency Treatment Regimens

Statin clinical trials suggest an incidence of adverse muscular events of ~ 1.5 – 3%, but the true incidence of…

Tolerability of Statin Therapy in Children

Regardless of the low number of children who will require treatment, obstacles remain for these pediatric patients. Medications commonly associated…

A New Definition and Key Considerations for ASCVD Risk Reduction in the Statin Intolerant Patient

My Statin or My Sarcolemma? Could Vitamin D Provide Some Answers for Improved Statin Compliance?

Data from the Cholesterol and Recurrent Events (CARE), Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), and Scandinavian Simvastatin Survival…

Bempedoic Acid Therapy for Patients with Statin Intolerance

Despite decades of progress in lipid lowering therapy, adequate LDL-C reduction remains a laudable but difficult to achieve goal, especially…

The Lipid Panel – Pharmacology: What Clinicians Should Know

Statins and Brain Fog: Confusing for Patients, Prescribers, and Me

HMG-CoA reductase inhibitors (statins) were FDA-approved in 1987 and their introduction has revolutionized lipid and cardiovascular (CV) management for the…

NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient

NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant…

Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association

Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association

Dyslipidemia Management in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Nonalcoholic fatty liver disease (NAFLD) is the accumulation of hepatic fat in ≥ 5% of hepatocytes in the absence of…

Episode 3: Autoimmune Statin Induced Myopathy: What Everyone Needs to Know

In this episode of Industry Innovations, host Dr. Alan Brown sits down with Dr. Lisa Christopher-Stine, a leading expert in…